Skip to main content

Advertisement

SpringerLink
Log in

De-Escalation of Local-Regional Therapy for Older Breast Cancer Patients

  • Local-Regional Evaluation and Therapy (A Kong, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Over the past decade, prospective clinical trials and retrospective data have changed clinical guidelines for the treatment of older patients, most notably those patients with early, hormone receptor-positive, clinically node-negative breast cancer. Here is a comprehensive review of the literature supporting de-escalation of local-regional therapy in older patients with breast cancer.

Recent Findings

The de-escalation of treatment in elderly patients includes minimizing surgical interventions and adjuvant radiation therapy. Current Choosing Wisely® guidelines recommend considering the omission of surgical staging of the axilla in patients ≥ 70 with early-stage, hormone receptor-positive breast cancer. Primary endocrine therapy may be a suitable option for older patients with hormone receptor-positive breast cancer and short life-expectancy. The long-term results of the CALGB 9343 clinical trial reveal that radiotherapy omission is not associated with a survival benefit in patients ≥ 70 with early-stage, hormone receptor-positive, node-negative breast cancer, who receive 5 years of adjuvant endocrine therapy. The results of the RAPID trial support that shorter courses of radiation therapy are non-inferior to standard therapy and may be of significant value to older patients who require radiation. In addition, intraoperative radiotherapy may be useful in older patients with mobility issues who have higher-risk tumors and the current TARGIT-E aims to assess IORT in patients ≥ 70 with hormone receptor-positive tumors.

Summary

Select older patients with breast cancer may benefit from the omission of axillary staging, less aggressive breast surgery, and shorter courses or total omission of radiation therapy. Current studies aim to continue to define the appropriate criteria for which older patients can benefit from de-escalation of local-regional therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cancer Stats: United States Cancer Statistics. Centers for Disease Control and Prevention. https://gis.cdc.gov/Cancer/USCS/DataViz.html. Accessed 21 June 2020.

  2. National Cancer Institute. Study Forecasts New Breast Cancer Cases by 2030. https://www.cancer.gov/news-events/cancer-currents-blog/2015/breast-forecast. Accessed 21 June 2020.

  3. Span P. For elderly women with breast cancer, surgery may not be the best option. The New York Times, [online] 2018. https://www.nytimes.com/2018/09/14/health/breast-cancer-surgery-elderly.html. Accessed 21 June 2020.

  4. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 4.2020. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 21 June 2020.

  5. •• NCCN Clinical Practice Guidelines in Oncology. Older Adult Oncology Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf. Accessed 21 June 2020. National cancer guidelines with considerations for older adults with breast cancer.

  6. Sada A, Day CN, Hoskin TL, Degnim AC, Habermann EB, Hieken TJ. Mastectomy and immediate breast reconstruction in the elderly: Trends and outcomes. Surgery. 2019;166(4):709–14. https://doi.org/10.1016/j.surg.2019.05.055.

    Article  PubMed  Google Scholar 

  7. Agborbesong O, Helmer SD, Reyes J, Strader LA, Tenofsky PL. Breast cancer treatment in the elderly: do treatment plans that do not conform to NCCN recommendations lead to worse outcomes? Am J Surg. 2020;220(2):381–4. https://doi.org/10.1016/j.amjsurg.2019.12.007.

    Article  PubMed  Google Scholar 

  8. • Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–7. https://doi.org/10.1056/NEJMoa040587. Initial results of the CALGB 9343 trial, demonstrating that in women age 70 with cT1-T2 N0 hormone-receptor positive tumors who undergo lumpectomy, radiation can be omitted if women receive 5 years of endocrine therapy with no difference in overall or distant disease-free survival.

  9. •• Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7. https://doi.org/10.1200/JCO.2012.45.2615Long-term results of the CALGB 9343 trial, demonstrating that in women age ≥70 with cT1-T2 N0 hormone-receptor positive tumors who undergo lumpectomy, radiation can be omitted if women receive 5 years of endocrine therapy with no difference in overall or distant disease-free survival.

  10. •• Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial [published correction appears in Lancet Oncol. 2015 Mar;16(3):e105]. Lancet Oncol. 2015;16(3):266–73. https://doi.org/10.1016/S1470-2045(14)71221-5Randomized control trial that demonstrated that in women age ≥65 with T1-T2 (up to 3cm) N0, hormone-receptor positive tumors who receive endocrine therapy, ipsilateral recurrence is low enough to allow for omission of radiation in some patients.

  11. Yen TW, Fan X, Sparapani R, Laud PW, Walker AP, Nattinger AB. A contemporary, population-based study of lymphedema risk factors in older women with breast cancer. Ann Surg Oncol. 2009;16(4):979–88. https://doi.org/10.1245/s10434-009-0347-2.

    Article  PubMed  PubMed Central  Google Scholar 

  12. •• Liang S, Hallet J, Simpson JS, Tricco AC, Scheer AS. Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: a systematic review and meta-analysis. J Geriatr Oncol. 2017;8(2):140–7 Included two randomized control trials (using PRISMA guidelines) and found that omission of axillary staging in cN0 elderly patients had an increase in regional recurrence, but no difference on survival.

    Article  PubMed  Google Scholar 

  13. • Welsh JL, Hoskin TL, Day CN, Habermann EB, Goetz MP, Boughey JC. Predicting nodal positivity in women 70 years of age and older with hormone receptor-positive breast cancer to aid incorporation of a society of surgical oncology choosing wisely guideline into clinical practice. Ann Surg Oncol. 2017;24(10):2881–8. Utilizing the NCDB, the authors created a model that demonstrated that early stage, low grade tumors have a lower rate of nodal positive disease.

  14. Greer LT, Rosman M, Charles Mylander W, Liang W, Buras RR, Chagpar AB, et al. A prediction model for the presence of axillary lymph node involvement in women with invasive breast cancer: a focus on older women. Breast J. 2014;20(2):147–53. https://doi.org/10.1111/tbj.12233.

    Article  PubMed  Google Scholar 

  15. • Choosing Wisely® Society of Surgical Oncology. Don’t routinely use sentinel node biopsy in clinically node negative women ≥70 years of age with early stage hormone receptor positive, HER2 negative invasive breast cancer. https://www.choosingwisely.org/clinician-lists/sso-sentinel-node-biopsy-in-node-negative-women-70-and-over/. Accessed 23 June 2020. Practice changing guideline on SLNB omission in older patients with early stage and favorable tumors.

  16. • Martelli G, Boracchi P, Ardoino I, Lozza L, Bohm S, Vetrella G, et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012;256(6):920–4. https://doi.org/10.1097/SLA.0b013e31827660a8. Fifteen year follow-up of a randomized clinical trial in 238 older breast cancer patients with cT1 N0 disease that revealed no difference in rates of distant metastasis, overall survival, or breast-cancer specific survival between those that received an ALND vs those that did not.

  17. Calderon E, Webb C, Kosiorek HE, Richard J, Gray MD, Cronin P, et al. Are we choosing wisely in elderly females with breast cancer? Am J Surg. 2019;218(6):1229–33. https://doi.org/10.1016/j.amjsurg.2019.08.004.

    Article  PubMed  Google Scholar 

  18. •• Christian N, Heelan Gladden A, Friedman C, Gleisner-Patton A, Murphy C, Kounalakis N, et al. Increasing omission of radiation therapy and sentinel node biopsy in elderly patients with early stage, hormone-positive breast cancer. Breast J. 2020;26(2):133–8. https://doi.org/10.1111/tbj.13483Retrospective analysis that found that since the Choosing Wisely ® guidelines have been released, there has been a decrease in the use of adjuvant radiation and nodal staging for women >70 years of age with early-stage, hormone-receptor positive breast cancer.

    Article  CAS  PubMed  Google Scholar 

  19. • Tamirisa N, Thomas SM, Fayanju OM, et al. Axillary nodal evaluation in elderly breast cancer patients: potential effects on treatment decisions and survival. Ann Surg Oncol. 2018;25(10):2890–8. https://doi.org/10.1245/s10434-018-6595-2. Analysis of the NCDB that revealed that older patients with node positive disease were more likely to receive adjuvant therapies with improved overall survival.

  20. • Sun SX, Hollenbeak CS, Leung AM. Deviation from the standard of care for early breast cancer in the elderly: what are the consequences? Ann Surg Oncol. 2015;22(8):2492–9. https://doi.org/10.1245/s10434-014-4290-5. SEER database analysis which demonstrated that as women age, those with Stage 1 cancer are less likely to receive standard care and may negatively impact survival.

  21. Hamaker ME, Bastiaannet E, Evers D, Water W, Smorenburg CH, Maartense E, et al. Omission of surgery in elderly patients with early stage breast cancer. Eur J Cancer. 2013;49(3):545–52. https://doi.org/10.1016/j.ejca.2012.08.010.

    Article  PubMed  Google Scholar 

  22. Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, Ballman K, et al. Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat. 2017;163(2):391–8. https://doi.org/10.1007/s10549-017-4188-6.

    Article  PubMed  PubMed Central  Google Scholar 

  23. University of California San Francisco. ePrognosis. https://eprognosis.ucsf.edu/index.php. Accessed 29 June 2020.

  24. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–31. https://doi.org/10.1200/JCO.2007.10.6559.

    Article  PubMed  Google Scholar 

  25. Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;(1):CD004272. Published 2006 Jan 25. https://doi.org/10.1002/14651858.CD004272.pub2.

  26. Garimella V, Hussain T, Agarwal V, Radhakrishna S, Fox JN, Kneeshaw PJ, et al. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker. Int J Surg. 2014;12(8):821–6. https://doi.org/10.1016/j.ijsu.2014.06.009.

    Article  PubMed  Google Scholar 

  27. de Glas NA, Jonker JM, Bastiaannet E, de Craen AJ, van de Velde CJ, Siesling S, et al. Impact of omission of surgery on survival of older patients with breast cancer. Br J Surg. 2014;101(11):1397–404. https://doi.org/10.1002/bjs.9616.

    Article  PubMed  Google Scholar 

  28. •• Johnston SJ, Kenny FS, Syed BM, Robertson JF, Pinder SE, Winterbottom L, et al. A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Ann Oncol. 2012;23(9):2296–300. https://doi.org/10.1093/annonc/mdr630Long-term follow-up of 153 elderly patients with early, node-negative hormone-receptor positive, breast cancer were randomized to tamoxifen or tamoxifen and surgery. There was no difference in recurrence, metastasis, disease-specific or overall survival, but the tamoxifen only group did have higher failure rates for local control.

    Article  CAS  PubMed  Google Scholar 

  29. • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2. Meta-analysis that found after breast-conserving surgery, radiation therapy halves the rate at which the disease recurs and reduces the breast cancer death rate by about a sixth.

  30. Weberpals J, Jansen L, Müller OJ, Brenner H. Long-term heart-specific mortality among 347,476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J. 2018;39(43):3896–903. https://doi.org/10.1093/eurheartj/ehy167.

    Article  CAS  PubMed  Google Scholar 

  31. Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. Version 2. J Clin Oncol. 2017;35(15):1641–9. https://doi.org/10.1200/JCO.2016.72.0722.

    Article  PubMed  PubMed Central  Google Scholar 

  32. • Arraras JI, Manterola A, Illarramendi JJ, Asin G, de la Cruz S, Ibañez B, et al. Quality of life evolution in elderly survivors with localized breast cancer treated with radiotherapy over a three-year follow-up. Breast. 2018;41:74–81. https://doi.org/10.1016/j.breast.2018.06.010. In older breast cancer patients, quality of life did not vary by local treatment type.

  33. •• Manyam BV, Tendulkar R, Cherian S, Vicini F, Badiyan SN, Shah C. Evaluating candidacy for hypofractionated radiation therapy, accelerated partial breast irradiation, and endocrine therapy after breast conserving surgery: a Surveillance Epidemiology and End Results (SEER) analysis. Am J Clin Oncol. 2018;41(6):526–31. https://doi.org/10.1097/COC.0000000000000332Analysis of the SEER database that showed a large portion of older women with early-stage breast cancer are eligible for shorter courses of radiation therapy, or omission of radiation therapy when appropriately applying guidelines and clinical trial inclusion criteria.

    Article  PubMed  Google Scholar 

  34. • Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20. https://doi.org/10.1056/NEJMoa0906260. Ten year follow-up of early stage breast cancer patients which found that accelerated, hypofractionated whole-breast irradiation was not inferior to standard radiation treatment in women who underwent lumpectomy.

  35. Sanz J, Zhao M, Rodríguez N, Granado R, Foro P, Reig A, et al. Once-weekly hypofractionated radiotherapy for breast cancer in elderly patients: efficacy and tolerance in 486 patients. Biomed Res Int. 2018;2018:8321871–9. https://doi.org/10.1155/2018/8321871.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Fiorentino A, Gregucci F, Mazzola R, Figlia V, Ricchetti F, Sicignano G, et al. Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities. Radiol Med. 2019;124(4):309–14. https://doi.org/10.1007/s11547-018-0976-2.

    Article  PubMed  Google Scholar 

  37. Cante D, Petrucci E, Sciacero P, Piva C, Ferrario S, Bagnera S, et al. Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer. Med Oncol. 2017;34(9):152. https://doi.org/10.1007/s12032-017-1020-4.

    Article  PubMed  Google Scholar 

  38. • De Santis MC, Bonfantini F, Di Salvo F, Fiorentino A, Dispinzieri M, Caputo M, et al. Hypofractionated whole-breast irradiation with or without boost in elderly patients: clinical evaluation of an Italian experience. Clin Breast Cancer. 2018;18(5):e1059–66. https://doi.org/10.1016/j.clbc.2018.04.003. Prospective clinical trial in older patients which demonstrated that that hypofractionated radiation therapy is effective and well tolerated. Routine boost in patients over 65 is not justified.

  39. Rovea P, Fozza A, Franco P, De Colle C, Cannizzaro A, Di Dio A, et al. Once-weekly hypofractionated whole-breast radiotherapy after breast-conserving surgery in older patients: a potential alternative treatment schedule to daily 3-week hypofractionation. Clin Breast Cancer. 2015;15(4):270–6. https://doi.org/10.1016/j.clbc.2014.12.011.

    Article  PubMed  Google Scholar 

  40. •• Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7(2):73–9. https://doi.org/10.1016/j.prro.2016.09.007ASTRO guidelines for those patients who are suitable candidates for APBI.

    Article  PubMed  Google Scholar 

  41. •• Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019;394(10215):2165–72. https://doi.org/10.1016/S0140-6736(19)32515-2Randomized controlled clinical trial that found external beam ABPI was non-inferior to whole-breast radiation, but did have higher rates of moderate late toxicity and poorer cosmesis.

    Article  PubMed  Google Scholar 

  42. Ott OJ, Strnad V, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al. GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: early toxicity and patient compliance. Radiother Oncol. 2016;120(1):119–23. https://doi.org/10.1016/j.radonc.2016.06.019.

    Article  PubMed  Google Scholar 

  43. Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383(9917):603–13. https://doi.org/10.1016/S0140-6736(13)61950-9 Erratum in: Lancet. 2014 Feb 15;383(9917):602.

    Article  PubMed  Google Scholar 

  44. Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomized controlled equivalence trial. Lancet Oncol. 2013;14:1269–77.

    Article  PubMed  Google Scholar 

  45. Vaidya JS, Bulsara M, Saunders C, Flyger H, Tobias JS, Corica T, et al. Effect of delayed targeted intraoperative radiotherapy vs whole-breast radiotherapy on local recurrence and survival: long-term results from the TARGIT-A randomized clinical trial in early breast cancer. JAMA Oncol. 2020:e200249. https://doi.org/10.1001/jamaoncol.2020.0249.

  46. Jacobs DHM, Horeweg N, Straver M, Roeloffzen EMA, Speijer G, Merkus J, et al. Health-related quality of life of breast cancer patients after accelerated partial breast irradiation using intraoperative or external beam radiotherapy technique. Breast. 2019;46:32–9. https://doi.org/10.1016/j.breast.2019.04.006.

    Article  CAS  PubMed  Google Scholar 

  47. Jacobs DHM, Speijer G, Petoukhova AL, Roeloffzen EMA, Straver M, Marinelli A, et al. Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients. Breast Cancer Res Treat. 2018;169(3):549–59. https://doi.org/10.1007/s10549-018-4712-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Abbott AM, Valente SA, Loftus L, Tendulkar RD, Greif JM, Bethke KP, et al. A multi-institutional analysis of intraoperative radiotherapy for early breast cancer: does age matter? Am J Surg. 2017;214(4):629–33. https://doi.org/10.1016/j.amjsurg.2017.06.018.

    Article  CAS  PubMed  Google Scholar 

  49. •• National Institutes of Health, ClinicalTrials.gov. Prospective phase II study of intraoperative radiotherapy (IORT) in elderly patients with small breast cancer (TARGIT-E). https://clinicaltrials.gov/ct2/show/NCT01299987. Accessed 13 July 2020. Ongoing clinical trial that will evaluate the safety and efficiacy of IORT in women age ≥70 with small, hormone-receptor positive, node negative tumors.

  50. Paulsson AK, Fowble B, Lazar AA, Park C, Sherertz T. Radiotherapy utilization for patients over age 60 with early stage breast cancer. Clin Breast Cancer. 2020;20(2):168–73. https://doi.org/10.1016/j.clbc.2019.10.005.

    Article  PubMed  Google Scholar 

  51. Bazan JG, Fisher JL, Park KU, Marcus EA, Bittoni MA, White JR. Assessing the impact of CALGB 9343 on surgical trends in elderly-women with stage I ER+ breast cancer: a SEER-based analysis. Front Oncol. 2019;9:621. https://doi.org/10.3389/fonc.2019.00621.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Palta M, Palta P, Bhavsar NA, Horton JK, Blitzblau RC. The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. Cancer. 2015;121(2):188–93. https://doi.org/10.1002/cncr.28937.

    Article  PubMed  Google Scholar 

  53. • Cortina CS, Agarwal S, Mulder LL, Poirier J, Rao R, Ansell DA, et al. Are providers and patients following hormonal therapy guidelines for patients over the age of 70? The influence of CALGB 9343. Clin Breast Cancer. 2018;18(6):e1289–92. https://doi.org/10.1016/j.clbc.2018.07.004. Retrospective cohort study that found older early stage breast cancer patients, increase age was associated with no receiving hormonal therapy, usually due to lack of benefit by providers.

  54. Nichol AM, Chan EK, Lucas S, Smith SL, Gondara L, Speers C, et al. The use of hormone therapy alone versus hormone therapy and radiation therapy for breast cancer in elderly women: a population-based study. Int J Radiat Oncol Biol Phys. 2017;98(4):829–39. https://doi.org/10.1016/j.ijrobp.2017.02.094.

    Article  PubMed  Google Scholar 

  55. Dispinzieri M, La Rocca E, Meneghini E, Fiorentino A, Lozza L, Di Cosimo S, et al. Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy. Med Oncol. 2018;35(7):107. https://doi.org/10.1007/s12032-018-1165-9.

  56. Chesney TR, Yin JX, Rajaee N, Tricco AC, Fyles AW, Acuna SA, et al. Tamoxifen with radiotherapy compared with tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: a systematic review and meta-analysis. Radiother Oncol. 2017;123(1):1–9. https://doi.org/10.1016/j.radonc.2017.02.019.

    Article  CAS  PubMed  Google Scholar 

  57. • Matuschek C, Bölke E, Haussmann J, Mohrmann S, Nestle-Krämling C, Gerber PA, et al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials. Radiat Oncol. 2017;12(1):60. https://doi.org/10.1186/s13014-017-0796-x. Meta-analysis which found that radiation therapy reduced local recurrence in older breast cancer patients with low-risk tumors, but did not improve overall survival.

  58. Inoue H, Hirano A, Ogura K, Kamimura M, Hattori A, Yukawa H, et al. Breast-conserving surgery without radiation in elderly women with early breast cancer. Surg Oncol. 2019;31:22–5. https://doi.org/10.1016/j.suronc.2019.08.008.

    Article  PubMed  Google Scholar 

  59. Tang L, Matsushita H, Jingu K. Controversial issues in radiotherapy after breast-conserving surgery for early breast cancer in older patients: a systematic review. J Radiat Res. 2018;59(6):789–93. https://doi.org/10.1093/jrr/rry071.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Cortina CS, Woodfin AA, Tangalakis LL, Wang X, Son JD, Poirier J, et al. Treating positive axillary disease in elderly breast cancer patients: the impact of age on radiation therapy. Breast Care. 2020. In press. https://doi.org/10.1159/000508243.

  61. •• Eaton BR, Jiang R, Torres MA, Kahn ST, Godette K, Lash TL, et al. Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer. Cancer. 2016;122(19):3059–68. https://doi.org/10.1002/cncr.30142Retrospective review of the SEER database examining women age ≥70 with T1-T2, node negative, hormone-receptor negative breast cancer found that those women who had radiation therapy, had lower incidence of breast cancer death at years.

    Article  CAS  PubMed  Google Scholar 

  62. • Daugherty EC, Daugherty MR, Bogart JA, Shapiro A. Adjuvant radiation improves survival in older women following breast-conserving surgery for estrogen receptor-negative breast cancer. Clin Breast Cancer. 2016;16(6):500–506.e2. https://doi.org/10.1016/j.clbc.2016.06.017. SEER database analysis that found in older women with T1 hormone receptor positive tumor, the addition of radiation therapy did improve survival.

  63. Valli M, Cima S, Fanti P, Muoio B, Vanetti A, Azinwi CN, et al. The role of radiotherapy in elderly women with early-stage breast cancer treated with breast conserving surgery. Tumori. 2018;104(6):429–33. https://doi.org/10.1177/0300891618792465.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI, 53226, USA

    Chandler S. Cortina

Authors
  1. Chandler S. Cortina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chandler S. Cortina.

Ethics declarations

Conflict of Interest

The author has no relevant disclosures to report. This article does not contain any studies with human or animal subjects performed by any of the authors. The Author ICJME COI is included separately.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Local-Regional Evaluation and Therapy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cortina, C.S. De-Escalation of Local-Regional Therapy for Older Breast Cancer Patients. Curr Breast Cancer Rep 12, 344–350 (2020). https://doi.org/10.1007/s12609-020-00395-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-020-00395-8

Keywords

Search

Navigation